The partnership to market and distribute Austedo, a treatment for neurodegenerative and movement disorders, through Teva Pharmaceutical Investments Singapore with Jiangsu Nhwa Pharmaceutical, indicates a strategic move to expand Teva's global footprint and access to new markets. This could lead to increased sales and revenue for Austedo, positively impacting TEVA's stock in the short term.